Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could infants with fast heartbeat stop meds sooner?

NCT ID NCT04837261

Disease control Sponsor: Tampere University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether infants with supraventricular tachycardia (SVT) can safely stop antiarrhythmic medication after just 4 months instead of longer. Researchers followed 107 infants aged 6 months or younger who were treated with drugs like propranolol or flecainide. The main goal was to see how many had a return of SVT after stopping medication early.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Propranolol, Flecainide, Amiodarone
What this could lead to
If successful, this could show that a shorter course of medication is safe and effective for infants with SVT, reducing drug exposure.
What could go wrong
This is an observational study, not a randomized trial, so results may be less reliable. The shorter course might lead to more recurrences of SVT.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

107 people

The number who actually took part.

Started

Apr 2021

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Infants age less than 6 months with SVT due to AVRT or AVNRT

Ages

Up to 6 months

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 6 months or less * Documented SVT due to AVRT or AVNRT Exclusion Criteria: * Age \> 6 months * Ectopic atrial tachycardia * Atrial flutter * Atrial fibrillation * Permanent junctional reciprocating tachycardia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Supraventricular tachycardia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac Tachycardia, Supraventricular

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Supraventricular tachycardia

Contacts and locations

Locations

  • Central Finland Central Hospital

    Jyväskylä, Central Finland, 40620, Finland

  • Helsinki University Hospital

    Helsinki, Uusimaa, 00029, Finland

  • Hämeenlinna Central Hospital

    Hämeenlinna, Kanta-Häme, 13530, Finland

  • Kajaani Central Hospital

    Kajaani, Kainuu, 87300, Finland

  • Kokkola Central Hopsital

    Kokkola, Keski-Pohjanmaa, 67200, Finland

  • Kuopio University Hospital

    Kuopio, Northern Savonia, 70029, Finland

  • Kymenlaakso Central Hospital

    Kotka, Region of Kymenlaakso, 48210, Finland

  • Lahti Central Hospital

    Lahti, Paijat-Hame Region, 15850, Finland

  • Lapland Central Hospital

    Rovaniemi, Lapland, 96101, Finland

  • Mikkeli Central Hospital

    Mikkeli, South Savo, 50100, Finland

  • North Karelia Central Hospital

    Joensuu, Pohjois-Karjala, 80210, Finland

  • Oulu University Hospital

    Oulu, North Ostrobothnia, 90220, Finland

  • Sakunta Central Hospital

    Pori, Satakunta, 28500, Finland

  • Seinäjoki Central Hospital

    Seinäjoki, South Ostrobothnia, 60220, Finland

  • South Karelia Central Hospital

    Lappeenranta, South Karelia Region, 53130, Finland

  • Tampere University Hospital

    Tampere, Pirkanmaa, 33520, Finland

  • Turku University Hospital

    Turku, Southwest, 20521, Finland

  • Vaasa Central Hospital

    Vaasa, Pohjanmaa, 65130, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.